

- Clinicians should offer HBV vaccination with the 3-dose Engerix-B or the 2-dose Hepivis-B vaccine series (A1) or the 2-dose Hepivis-B vaccine series (A2†) to patients with negative test results for HBsAg, anti-HBs, and anti-HBc (A2†) to patients with negative test results for HBsAg, anti-HBs, and anti-HBc.
- Clinicians should not defer initial HBV vaccination in patients with a CD4 count < 200 cells/mm³ who are at risk for HBV infection. (A2)
- Patients should repeat anti-HBs testing 4 to 16 weeks, based on the patient's visit schedule, after completion of the vaccination series to ensure immunity (anti-HBs ≥ 10 IU/mL). (A3)
- In a patient with negative HBsAg, negative anti-HBs, and positive anti-HBc test results (isolated anti-HBc positive), the clinician should offer a 1-time dose of HBV vaccine. (A2)
- Repeat anti-HBs testing 8 weeks after vaccination, and if the anti-HBs titer is < 100 IU/mL, complete the HBV vaccine series and repeat anti-HBs testing 8 weeks after the last vaccine. (A2)
- If vaccination is refused or if follow-up anti-HBs titer testing cannot be assured, perform HBV DNA testing to evaluate for occult HBV infection. (A2)
- Clinicians should not have immunity to HBV. (A3)
- In previously vaccinated patients with anti-HBs levels < 10 IU/mL (vaccine nonresponse), clinicians should recommend revaccination with the Hepivis-B vaccine series or a double dose of the vaccine series previously administered. (A2)

Assessment Before HBV Treatment

- Before initiating HBV treatment in patients with HIV, clinicians should obtain a complete physical examination and medical history, including the use of hepatotoxic medications (A*); noninvasive fibrosis evaluation (A2†); baseline ultrasonography for HCC (A2†); and the following laboratory testing: CBC, albumin, bilirubin, alkaline phosphatase, PT/INR, ALT, AST, and a basic metabolic panel. (A*)
- Clinicians should refer patients with HIV/HBV coinfection and cirrhosis to a gastroenterologist or hepatologist to assess and manage complications of portal hypertension. (A3)
- In patients with HIV/HBV coinfection and cirrhosis, clinicians should screen for HCC with ultrasound every 6 months. (A2†)

HBV Vaccination

ALL RECOMMENDATIONS (continued from P.1)

P.2

- Clinicians should perform alcohol use screening in patients with HIV/HBV coinfection at baseline and at least annually and refer patients for treatment as needed. (A3)
- Clinicians should educate patients about the detrimental effects of alcohol use on the course of HBV infection and counsel patients with underlying liver disease to abstain from or minimize alcohol use. (A*)
- Clinicians should perform anti-HAV IgG or total (IgM and IgG) serum testing and administer the full HAV vaccine series in patients who are not immune to HAV. (A3)
- Clinicians should determine patients' HCV status by medical history and serum testing and recommend treatment with DAA therapy if chronic HCV infection is diagnosed. (A1)
- Clinicians should perform anti-HDV total (IgM and IgG) serum testing to screen for HDV in all patients with HIV/HBV coinfection. (B2)

HBV Treatment and Monitoring

- Clinicians should recommend immediate ART initiation for any patient with HIV/HBV coinfection who is not taking ART. (A1)
- Preferred: In patients with HIV and chronic HBV, clinicians should recommend an ART regimen that includes 2 agents active against HBV. Preferred regimens include a backbone of either TAF/FTC, TDF/FTC, or TDF/3TC. (A2)
- Clinicians should not prescribe a 2-drug regimen of TAF/FTC, TDF/FTC, or TDF/3TC alone to treat patients with HIV/HBV coinfection; a fully suppressive ART regimen is required. (A1)
- Nonadherence with or discontinuation of anti-HBV treatment may result in transaminase flares and hepatic damage. Clinicians should educate patients about the treatment adherence requirements (A*), and if treatment must be interrupted or discontinued, consult with a care provider experienced in HIV/HBV coinfection. (A3)
- Alternative: If a patient cannot or chooses not to take TDF or TAF, the clinician should initiate treatment with ETV and a fully suppressive ART regimen for HIV. (A3)
- Clinicians should offer pregnant patients treatment with an ART regimen that includes 2 agents active against both HIV and HBV, 3TC, FTC, TAF, and TDF can be used safely during pregnancy at standard doses. (A2†)

Assessment Before HBV Treatment

ALL RECOMMENDATIONS (continued from P.2)

P.3

ALL RECOMMENDATIONS (continued from P.3)

P.4

HBV Treatment and Monitoring

- After HBV treatment initiation, clinicians should perform the laboratory testing listed in the Table. (A3)
- If a patient being treated for chronic HBV develops signs or symptoms of acute hepatitis (nausea, vomiting, elevated ALT or bilirubin levels), the clinician should rule out HBV IRIS and HDV flare and consult with an HIV-experienced hepatologist. (A3)

ABBREVIATIONS

3TC, lamivudine; ALT, alanine transaminase; anti-HBc, hepatitis B core antibody; anti-HBe, antibody to HBeAg; anti-HBs, hepatitis B surface antibody; ART, antiretroviral therapy; AST, aspartate transaminase; CBC, complete blood count; DAA, direct-acting antiviral; ETV, entecavir; FTC, emtricitabine; HBeAg, hepatitis B e antigen; HBsAg, hepatitis B surface antigen; HAV, hepatitis A virus; HBV, hepatitis B virus; HCC, hepatocellular carcinoma; HCV, hepatitis C virus; HDV, hepatitis D virus; IgG, immunoglobulin G; IgM, immunoglobulin M; IRIS, immune reconstitution inflammatory syndrome; PT/INR, prothrombin time/international normalized ratio; TAF, tenofovir alafenamide; TDF, tenofovir disoproxil fumarate.

NEW YORK STATE LAW

- Clinicians must report all suspected or confirmed HBV infections, and specify acute or chronic, to the local health department of the area where the individual resides according to NYSDOH Communicable Diseases Reporting Requirements.

HIV CLINICAL RESOURCE ■ 1/4-FOLDED GUIDE

VISIT HIVGUIDELINES.ORG TO LEARN MORE OR VIEW COMPLETE GUIDE



PREVENTION AND MANAGEMENT OF HEPATITIS B VIRUS INFECTION IN ADULTS WITH HIV

NYSDOH AIDS INSTITUTE HIV CLINICAL GUIDELINE AUGUST 2022

ALL RECOMMENDATIONS P.1

HBV Screening and Diagnosis

- Clinicians should determine the HBV vaccination and immune status of patients with HIV by performing laboratory testing for HBsAg, anti-HBs, and anti-HBc (total). (A*)
- Clinicians should repeat laboratory screening annually in patients who are not immune to HBV, choose not to be vaccinated, and are at ongoing risk of acquiring HBV. (A3)
- In patients with positive baseline (screening) HBsAg test results, clinicians should perform HBeAg, anti-HBe, and HBV DNA testing to diagnose the phase of HBV infection. (B2†)
- If a patient with HIV and unknown HBsAg status has signs or symptoms of acute hepatitis (i.e., elevated ALT), the clinician should perform HBsAg, anti-HBc IgM, HBeAg, anti-HBe (A*), and HBV DNA (A3) testing along with other diagnostic testing for acute hepatitis.
- If acute HBV infection is confirmed and the patient is asymptomatic, the clinician should repeat ALT testing within 2 to 4 weeks to assess for symptoms of liver disease progression (B3) and repeat HBsAg, HBeAg, anti-HBe, and HBV DNA testing 6 months later to determine whether infection has cleared. (A3)
- If a patient with HIV and acute HBV is not taking ART, the clinician should recommend ART initiation. (A1)
- Clinicians should advise patients who have a positive HBsAg test result that they can transmit HBV (A*) and encourage sexually active patients to use effective barrier protection to reduce the risk of HBV transmission. (A2†)
- Clinicians should inform patients with HBV that their household contacts should be vaccinated and counsel the patients to avoid sharing items such as razors or toothbrushes that could expose others to HBV-contaminated blood. (A2†)
- For individuals who inject drugs, clinicians should offer or refer for substance use treatment, ensure access to clean needles and syringes, and provide harm reduction counseling. (A2†)



← Use this code with your phone's QR code reader to go directly to a mobile-friendly version of this guideline.


■ This 1/4-Folded Guide is a companion to the New York State Department of Health AIDS Institute guideline *Prevention and Management of Hepatitis B Virus Infection in Adults With HIV*. Full guideline is available at hivguidelines.org.

TABLE: RECOMMENDED MONITORING AFTER HBV TREATMENT INITIATION IN ADULTS WITH HIV

Laboratory Test	Every 3 Months	Every 6 Months	Every 12 Months
HBV DNA	Until HBV DNA is undetectable [a]	After HBV DNA is undetectable	
HBeAg			Check for HBeAg-negative result [b]
Electrolyte panel		X	
Serum creatinine		X	
Urinalysis [c]			X
Liver function panel [c]	Until HBV DNA is undetectable [a]	After HBV DNA is undetectable	

Notes:
 a. Undetectable is defined as <10 mIU/mL.
 b. Patients who have been taking anti-HBV treatment for several years may not convert to HBeAg-negative.
 c. See the NYSDOH AI guideline Laboratory Monitoring for Adverse Effects of ART > Frequency of Laboratory Monitoring During ART > Table 1: Minimum Laboratory Monitoring Frequency With Initiation of or Change in Antiretroviral Therapy for Patients <50 Years Old and Without Chronic Comorbidities.

FIGURE: Algorithm for HBV Screening and Vaccination in Patients With HIV



Notes:
 a. In patients with positive anti-HBc, negative anti-HBs, and negative HBsAg test results, vaccinate with 1 standard dose of HBV vaccine and check anti-HBs titer after 8 weeks. If titer is <100 mIU/mL, complete remaining doses in the vaccine series and recheck titer 8 weeks after the last vaccine.
 b. In patients with anti-HBs levels <10 mIU/mL (vaccine nonresponse), revaccination is recommended with the HepBisav-B vaccine series or a double dose of the vaccine series previously administered.
 c. A patient who is negative for all serologies and who does not respond to revaccination may have a primary nonresponse or chronic infection. HBV DNA testing may be used to detect the presence of chronic HBV infection.